文献速递乳腺癌放疗

个体化放疗方案在炎性乳腺癌中实现优异局部区域控制

Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach.
PubMed 文献 · Pract Radiat Oncol · 2019-05-24

该研究基于2007至2015年前瞻性数据库中的103例非转移性炎性乳腺癌患者,比较每日两次(BID)与每日一次(QD)术后放疗的局部区域控制与毒性。

要点

  • 依据年轻、新辅助反应不全、切缘阳性等危险因素将BID降级为QD,局部控制仍优异。
  • QD与BID术后放疗的毒性粗率无差异,但回顾性数据收集可能限制该比较。

核心结论

  • 依据临床危险因素个体化调整放疗方案与优异的局部区域控制相关。
  • 将术后放疗从BID降级为QD未明确降低毒性,但回顾性数据收集可能限制该比较。

研究设计与样本

  • 前瞻性收集数据库中的103例非转移性炎性乳腺癌患者,2007至2015年接受三联治疗。
  • 采用描述性统计比较 retrospectively 提取的放疗相关毒性率,Kaplan-Meier法分析无局部区域复发生存率。

主要发现

  • QD组中位剂量50.0 Gy/25次,中位推量10.0 Gy/5次;BID组中位剂量51.0 Gy/34次,中位推量15.0 Gy/10次。
  • QD与BID术后放疗的毒性粗率无差异。

关键数值与推荐

  • 年轻、新辅助治疗反应不完全和切缘阳性被识别为从剂量递增中最大获益的亚群。
  • BID术后放疗中位剂量51.0 Gy/34次,中位推量15.0 Gy/10次;QD术后放疗中位剂量50.0 Gy/25次,中位推量10.0 Gy/5次。

临床怎么用

  • 对具有年轻、新辅助反应不全或切缘阳性等危险因素的炎性乳腺癌患者,可考虑BID剂量递增放疗。
  • 对选择病例将术后放疗从BID降级为QD未显示明确毒性获益,需结合个体风险决策。

局限性

  • 回顾性提取毒性数据可能限制QD与BID毒性比较的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inflammatory breast cancer (IBC) has been characterized by high locoregional recurrence (LRR) rates even after trimodality therapy. We recently reported excellent locoregional control among patients treated since formal dedication of an IBC-specific clinic and research program in 2006. Institutionally, a standard twice-daily (BID) dose escalation regimen for all patients with IBC was de-escalated in select cases in 2006 after review demonstrated that young age, incomplete response to neoadjuvant therapy, and positive margins identified subsets with maximal benefit from dose escalation. We report local control and toxicity rates specific to BID versus once-daily (QD) radiation therapy approaches. METHODS AND MATERIALS: From a prospectively collected database, we identified 103 patients with nonmetastatic IBC who received trimodality therapy at our institution from 2007 to 2015. Descriptive statistics were used to describe the study cohort and compare retrospectively extracted rates of radiation therapy-associated toxicity. The actuarial rate of LRR-free survival was analyzed using the Kaplan-Meier method. RESULTS: The median follow-up is 3.6 years. Thirty-nine patients (37.9%) received postmastectomy radiation therapy (PMRT) to the chest wall and undissected regional lymphatics in QD fractions (median dose, 50.0 Gy in 25 fractions [fx]; median boost dose, 10.0 Gy in 5 fx) and 64 patients (62.1%) received BID PMRT (median dose, 51.0 Gy in 34 fx; median boost dose, 15.0 Gy in 10 fx). Crude rates of toxicity were not different between patients treated with QD or BID PMRT. Two BID patients (3.1%) and no QD patients (0.0%) experienced LRR (P = .53). The 3- and 5-year LRR-free survival were 95.1% and 100.0% for BID and QD patients, respectively (P = .25). CONCLUSIONS: Tailoring radiation therapy to clinical risk factors was associated with excellent locoregional control. De-escalation of PMRT from BID to QD was not clearly associated with reduced toxicity compared with BID, although retrospective data collection may limit this comparison.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stecklein SR, Rosso KJ, Nuanjing J, et al. Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019. PMID: 31132433. doi:10.1016/j.prro.2019.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。